Dr Lin
Geissler K et al. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. Br J Haematol 2024;205(5):1734-45. Abstract
Pratz KW et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 2024;99:615-24. Abstract
Venditti A et al. Fitness assessment in acute myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood Adv 2025;9(9): 2207-20. Abstract
Wei AH et al. How I treat patients with AML using azacitidine and venetoclax. Blood 2025;145(12):1237-50. Abstract
Zeidan AM et al. An all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 patients. ASCO 2025;Abstract 6504.
Dr Perl
Bazarbachi A et al. Challenging the adverse label: Diverse outcomes of ELN 2022 adverse cytogenetic subgroups in acute myeloid leukemia patients allografted in first remission: From EBMT ALWP. Am J Hematol 2025;100(8):1374-86. Abstract
Daver N et al. Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed acute myeloid leukemia. ASH 2025;Abstract 651.
Daver NG et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: A phase 1/2 study. Lancet Oncol 2024;25(3):388-99. Abstract
DiNardo CD et al. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 2025;39(4):854-63. Abstract
Döhner H et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood 2024;144(21):2211-22. Abstract
Fang Q et al. Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML): A multicenter, prospective, randomized phase II trial. ASH 2025;Abstract 650.
Fathi A et al. Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. ASH 2025;Abstract 6.
Lu J et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood 2025;145(22):2645-55. Abstract
Montesinos P et al. Quizartinib for newly diagnosed FLT3-internal tandem duplication-negative AML: The randomized, double-blind, placebo-controlled, phase II QUIWI study. J Clin Oncol 2025;[Online ahead of print]. Abstract
Dr Erba
Levis MJ et al. FLT3-ITD measurable residual disease from the QuANTUM-First trial. Blood Adv 2025;[Online ahead of print]. Abstract
Levis MJ et al. Correlation of baseline gene mutations with quizartinib efficacy in patients with FLT3-ITD-positive newly diagnosed acute myeloid leukemia in the phase 3 QuANTUM-First trial. ASH 2024;Abstract 848.
Levis MJ et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 2024;42:1766-75. Abstract
Luger S et al. Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD Negative rate: Results of the phase 2 randomized precog 0905 study in newly diagnosed FLT3 mutated AML. ASH 2024;Abstract 221.
Montesinos P et al. Quizartinib for newly diagnosed FLT3-internal tandem duplication-negative AML: The randomized, double-blind, placebo-controlled, phase II QUIWI study. J Clin Oncol 2025;[Online ahead of print]. Abstract
Short NJ et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol 2024;42:1499-508. Abstract
Yilmaz M et al. Phase I/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. EHA 2025;Abstract S142.
Dr Fathi
Cortes J et al. Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort. J Hematol Oncol 2025;18:102. Abstract
Cortes J et al. Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: A multicohort open-label phase 1/2 trial. J Hematol Oncol 2025;18:7. Abstract
DiNardo CD et al. Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitors for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML. J Clin Oncol 2025;43(24):2692-699. Abstract
Montesinos P et al. Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. Blood Adv 2025;9(20):5177-89. Abstract
Watts JM et al. Looking beyond the surface: olutasidenib and ivosidenib for treatment of mIDH1 acute myeloid leukemia. Curr Treat Options Oncol 2024;25(11):1345-53. Abstract
Wei A et al. Olutasidenib as maintenance therapy after treatment response in mutated IDH1 acute myeloid leukemia. EHA 2025;Abstract PF530.
Dr Eytan Stein
Aldoss I et al. Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study. ASH 2025;Abstract 1001.
Erba H et al. Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-M OR KMT2A-R acute myeloid leukemia (AML): Updated phase 1A/B results from KOMET-007. EHA 2025;Abstract S136.
Fathi AT et al. Ziftomenib combined with venetoclax/azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Interim phase 1a results from KOMET-007. ASH 2024;Abstract 2880.
Issa G et al. Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007. ASH 2025;Abstract 764.
Issa GC et al. Combination strategies with menin inhibitors for acute leukemia. Blood Cancer Discov 2025;6(6):547-60. Abstract
Issa GC et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol 2025;43(1):75-84. Abstract
Issa GC et al. How I treat acute myeloid leukemia with differentiation therapy. Blood 2025;145(12):1251-9. Abstract
Jen W-Y et al. Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. ASH 2025;Abstract 47.
Roboz G et al. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007. ASH 2025;Abstract 766.
Searle E et al. Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed/refractory acute leukemia patients with KMT2A and NPM1 alteration. ASH 2024;Abstract 212.
Zeidner J et al. Azacitidine, venetoclax, and revumenib for newly diagnosed older adults with acute myeloid leukemia (AML) and NPM1 mutation or KMT2A rearrangement: Updated results from the BEATAML consortium. EHA 2025;Abstract S138.
Zeidner J et al. Phase 1B study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: Interim results of dose escalation from the BEATAML consortium. EHA 2024;Abstract S134.